Australian radiopharmaceutical company, Cyclopharm Limited (ASX: CYC) is focused on innovative solutions in nuclear medicine, targeted towards lung health. Serving the global medicine community since 1986, the company’s proprietary medical device and pharmaceutical products are made available under TechnegasTM, which is considered as the industry gold-standard in diagnostic functional lung imaging technology. Cyclopharm distributes its products in 57 countries with more than 1,500 nuclear medicine departments using TechnegasTM.